These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 8167339)

  • 1. Alteration of fibrin network by activated protein C.
    Gruber A; Mori E; del Zoppo GJ; Waxman L; Griffin JH
    Blood; 1994 May; 83(9):2541-8. PubMed ID: 8167339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dissolution of human cross-linked plasma fibrin clots by the equimolar human plasmin-derived light (B) chain-streptokinase complex. The acceleration of clot lysis by pretreatment of fibrin clots with the light (B) chain.
    Summaria L; Boreisha IG; Arzadon L; Robbins KC
    Thromb Res; 1977 Sep; 11(3):377-89. PubMed ID: 144332
    [No Abstract]   [Full Text] [Related]  

  • 3. The effect of activated protein C on fibrinolysis in cell-free plasma can be attributed specifically to attenuation of prothrombin activation.
    Bajzar L; Nesheim M
    J Biol Chem; 1993 Apr; 268(12):8608-16. PubMed ID: 8473306
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Disintegration and reorganization of fibrin networks during tissue-type plasminogen activator-induced clot lysis.
    Meh DA; Mosesson MW; DiOrio JP; Siebenlist KR; Hernandez I; Amrani DL; Stojanovich L
    Blood Coagul Fibrinolysis; 2001 Dec; 12(8):627-37. PubMed ID: 11734662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of fibrin structure on plasmin-mediated dissolution of plasma clots.
    Carr ME; Alving BM
    Blood Coagul Fibrinolysis; 1995 Sep; 6(6):567-73. PubMed ID: 7578900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Urokinase-induced fibrin clot lysis and its inhibition by plasma.
    Carlin G
    Ups J Med Sci; 1980; 85(1):29-33. PubMed ID: 6446181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aβ delays fibrin clot lysis by altering fibrin structure and attenuating plasminogen binding to fibrin.
    Zamolodchikov D; Strickland S
    Blood; 2012 Apr; 119(14):3342-51. PubMed ID: 22238323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between staphylokinase, plasmin(ogen), and fibrin. Staphylokinase discriminates between free plasminogen and plasminogen bound to partially degraded fibrin.
    Sakharov DV; Lijnen HR; Rijken DC
    J Biol Chem; 1996 Nov; 271(44):27912-8. PubMed ID: 8910391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An analysis of mechanisms underlying the antifibrinolytic properties of radiographic contrast agents.
    Farrehi PM; Zhu Y; Fay WP
    J Thromb Thrombolysis; 2001 Dec; 12(3):273-81. PubMed ID: 11981110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular mechanisms of the effect of ultrasound on the fibrinolysis of clots.
    Chernysh IN; Everbach CE; Purohit PK; Weisel JW
    J Thromb Haemost; 2015 Apr; 13(4):601-9. PubMed ID: 25619618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro simulation of therapeutic thrombolysis with microtiter plate clot-lysis assay.
    Stief TW
    Clin Appl Thromb Hemost; 2006 Jan; 12(1):21-32. PubMed ID: 16444431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue plasminogen activator (tPA) inhibits plasmin degradation of fibrin. A mechanism that slows tPA-mediated fibrinolysis but does not require alpha 2-antiplasmin or leakage of intrinsic plasminogen.
    Wu JH; Diamond SL
    J Clin Invest; 1995 Jun; 95(6):2483-90. PubMed ID: 7769094
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparative study of the efficacy and specificity of tissue plasminogen activator and pro-urokinase: demonstration of synergism and of different thresholds of non-selectivity.
    Gurewich V; Pannell R
    Thromb Res; 1986 Oct; 44(2):217-28. PubMed ID: 3097872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of affinities of urokinase and tissue plasminogen activator for fibrin clots.
    Homandberg GA; Wai T
    Thromb Res; 1989 Aug; 55(4):493-501. PubMed ID: 2510355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of flow on lysis of plasma clots in a plasma environment.
    Sakharov DV; Rijken DC
    Thromb Haemost; 2000 Mar; 83(3):469-74. PubMed ID: 10744155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activated human protein C prevents thrombin-induced thromboembolism in mice. Evidence that activated protein c reduces intravascular fibrin accumulation through the inhibition of additional thrombin generation.
    Gresele P; Momi S; Berrettini M; Nenci GG; Schwarz HP; Semeraro N; Colucci M
    J Clin Invest; 1998 Feb; 101(3):667-76. PubMed ID: 9449701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accelerated thrombolysis. In vitro evaluation of agents and methods of administration.
    Bookstein JJ; Saldinger E
    Invest Radiol; 1985 Oct; 20(7):731-5. PubMed ID: 2933363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.